We provide you with 20 years of free, institutional-grade data for OCGN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OCGN. Explore the full financial landscape of OCGN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about OCGN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Ocugen, Inc(NASDAQ:OCGN) 
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherit...
Website: http://www.ocugen.com
Founded: 2013
Full Time Employees: 16
CEO / Co-Founder: Shankar Musunuri
Sector: Healthcare
Industry: Biotechnology